Vera Therapeutics, Inc. (VERA)
$27.72-7.23%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.0B
- Beta
- 0.95
- P/E (TTM)
- -4.57
- Short % float
- 29.46%
- Days to cover
- 7.8
- SI change
- +1.2%
- 1W
- -7.07%
- 1M
- -20.91%
- vs SPY 1W
- -7.50%
- vs SPY 1M
- -22.97%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.37-0.97%
- ARQTSELLArcutis Biotherapeutics, Inc.$3.3BRECOVERYQ 11$26.58-1.35%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-2.24%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95+0.20%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -0$10.82-1.29%
- ALMSSELLAlumis Inc.$884MCRISISQ 1$7.16-1.40%
- PHARSELLPharming Group N.V.$693MCRISISQ -1$9.79-1.84%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on VERA?
- LOPJLB’s latest quantitative signal on Vera Therapeutics, Inc. (VERA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VERA in?
- Vera Therapeutics, Inc. (VERA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Vera Therapeutics, Inc. (VERA) do?
- Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to tr…